Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
35 hedge funds and large institutions have $987K invested in Unity Biotechnology in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 7 closing their positions.
520% more call options, than puts
Call options by funds: $31K | Put options by funds: $5K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
3.01% less ownership
Funds ownership: 18.01% → 15% (-3%)
13% less funds holding
Funds holding: 40 → 35 (-5)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
91% less capital invested
Capital invested by funds: $11.4M → $987K (-$10.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$110K |
| 2 |
HF
HRT Financial
New York
|
+$29.7K |
| 3 |
Morgan Stanley
New York
|
+$14.7K |
| 4 |
Renaissance Technologies
New York
|
+$3.51K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FH
Financial Harvest
Winter Park,
Florida
|
-$8.46M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$304K |
| 3 |
CM
Cercano Management
Bellevue,
Washington
|
-$42.9K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$24K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$21.4K |
UBX Hedge Fund Activity: Q2 2025 in Review
35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2025, worth a combined $987K — down 91% from $11.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of UBX and 2 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 10 added.
The largest buyer was UBS Group, adding an estimated $110K. The largest seller was Financial Harvest, exiting entirely with an estimated $8.46M sold.
- 35 institutional investors held Unity Biotechnology (UBX) as of Q2 2025, down from 40 in Q1 2025.
- Funds reported $987K of Unity Biotechnology stock for Q2 2025, down 91% quarter-over-quarter.
- 2 funds opened new Unity Biotechnology positions in Q2 2025 and 7 closed out, a net change of -5 holders.
- The largest Unity Biotechnology buyer in Q2 2025 was UBS Group, an estimated $110K added.
- The largest Unity Biotechnology seller in Q2 2025 was Financial Harvest, an estimated $8.46M sold.
Based on aggregated 13F filings for Q2 2025.